Evidence map›Paper›PMID 39201599›Full record

ArticleInternational journal of molecular sciences2024

Molecular Alterations Associated with Histologically Overt Stromal Response in Patients with Prostate Cancer.

Mutlay Sayan, Yetkin Tuac, Mahmut Akgul, Samet Kucukcolak, Elza Tjio, Dilara Akbulut, Luke W Chen, David D Yang, Shalini Moningi, Jonathan E Leeman and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Mutlay SayanDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0101-0951
Yetkin TuacDepartment of Statistics, Ankara University, Ankara 06100, Türkiye.ORCID 0000-0001-6590-3233
Mahmut AkgulDepartment of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, USA.ORCID 0000-0003-0929-0940
Samet KucukcolakDepartment of Pathology and Laboratory Medicine, Rutgers University, New Brunswick, NJ 07102, USA.
Elza TjioHistopathology Department, Harrogate District Hospital, Harrogate HG2 7SX, UK.
Dilara AkbulutLaboratory of Pathology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-2288-9667
Luke W ChenDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
David D YangDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5146-218X
Shalini MoningiDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Jonathan E LeemanDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Peter F OrioDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Anthony V D'AmicoDepartment of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Cagdas AktanDepartment of Medical Biology, Faculty of Medicine, Bandirma Onyedi Eylul University, Balikesir 10250, Türkiye.ORCID 0000-0002-9125-6444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer has substantial heterogeneity in clinical outcomes and therapeutic responses, posing challenges in predicting disease progression and tailoring treatment strategies. Recent studies have highlighted the potential prognostic value of evaluating the tumor microenvironment, including the presence of a histologically overt stromal response (HOST-response) characterized by peri-glandular stromal changes and architectural distortions. This retrospective study examined patient records from The Cancer Genome Atlas database to identify genomic alterations associated with the HOST-response in prostate cancer. Among 348 patients who underwent radical prostatectomy, 160 (45.98%) were identified as having a HOST-response. A gene expression analysis revealed 1263 genes with significantly higher expression in patients with a HOST-response. A protein-protein interaction network analysis identified seven hub genes (

Indexed as

Prostatic NeoplasmsTumor MicroenvironmentAgedBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisProstatectomyProtein Interaction MapsRetrospective StudiesStromal CellsBiomarkers, Tumorgenomic instabilityHOST-responseprostate cancertumor microenvironment

Identifiers

PMID39201599
PMCPMC11354361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.